Cytheris initiates new trial in HIV patients

Published: 15-Oct-2007
Regulatory Research & Development

Cytheris to expand clinical trial programme for recombinant human Interleukin-7 - CYT107


A clinical stage biopharmaceutical company is to expand its clinical trial programme for recombinant human Interleukin-7 - CYT107 with the initiation of a PhaseI/IIa clinical trial in HIV patients.

Cytheris will conduct the trial at sites in France, Italy, Canada and the US. The trials follow the launch of previously announced PhaseI/IIa trials of IL-7 in Hepatitis C and oncology. The announcement was made at a mini symposium in Sweden last month called Frontiers in Medicine.

  • Companies:
  • Cytheris
See more

You may also like

Regulatory

Cytheris publish new oncology data

Read more
A second phase 1 trial in oncology has highlighted the potential for Interleukin-7

Trending Articles

  1. COVID-19 still a significant risk for the immunocompromised, study finds AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
  2. US court lifts modified consent decree on Xellia’s Cleveland facility The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
  3. Lonza's AI-enabled small molecule development tool launches The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
  4. Broughton receives flexible scope ISO 17025 accreditation New certification allows accreditation without prior approval
  5. N4 Pharma and SRI to target and treat previously unreachable human cells The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Regulatory

Cytheris publish new oncology data

A second phase 1 trial in oncology has highlighted the potential for Interleukin-7
Regulatory

Laureate in agreement to manufacture lead product candidate for Cytheris

Laureate Pharma has entered into a cGMP contract manufacturing agreement with Cytheris
Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

US court lifts modified consent decree on Xellia’s Cleveland facility

The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Subscribe now